Document is current
Any future updates will be listed below
-
Authors
Zhao, Yan
Zhang, Litao
Wu, Liming
Duan, Xinsuo
Ji, Chao
Xiao, Rong
Ji, Mingkai
Liu, Lunfei
Yang, Bin
Hu, Guohong
Feng, Yanyan
Zhu, Jianjian
Li, Jianguo
Ding, Yangfeng
Huang, Haomin
Zhou, Qinghong
Xu, Yuyu
Zhang, Jianzhong
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05544591 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial
https://doi.org/10.1007/s13555-025-01368-4
-
Funding
Funding for this research was provided by:
Sunshine Guojian Pharmaceutical (Shanghai) Co.,Ltd
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 19 February 2025
First Online: 9 March 2025
Declarations
:
: Haomin Huang, Qinghong Zhou, and Yuyu Xu are employees of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.; Yan Zhao, Litao Zhang, Liming Wu, Xinsuo Duan, Chao Ji, Rong Xiao, Mingkai Ji, Lunfei Liu, Bin Yang, Guohong Hu, Yanyan Feng, Jianjian Zhu, Jianguo Li, Yangfeng Ding, and Jianzhong Zhang have nothing to disclose.
: This study adhered to the ethical principles of the Declaration of Helsinki for medical research involving human subjects and was conducted in accordance with Good Clinical Practice (GCP) guidelines. Before the study commenced, the clinical trial protocol, case report forms, informed consent forms, and other related documents were approved by the Peking University People’s Hospital Ethics Committee (approval number: 2022PHC022-001). All patients provided written informed consent for participation in the study.
